{
    "clinical_study": {
        "@rank": "53653", 
        "arm_group": [
            {
                "arm_group_label": "Beclometasone/Formoterol/Glycopyrrolate", 
                "arm_group_type": "Experimental", 
                "description": "CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid"
            }, 
            {
                "arm_group_label": "Beclometasone/Formoterol", 
                "arm_group_type": "Active Comparator", 
                "description": "Foster\u00ae 100/6 mcg 2 inhalations bid"
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to\n      demonstrate the superiority of the triple fixed combination of\n      Beclometasone+Formoterol+Glycopyrrolate administered via pMDI over the equivalent dose of\n      Foster\u00ae in COPD (Chronic Obstructive Pulmonary Disease) patients after 52 weeks of treatment"
        }, 
        "brief_title": "Efficacy of Fixed Combination of Beclomethasone + Formoterol + Glycopyrrolate Versus Foster\u00ae in Chronic Obstructive Pulmonary Diseases", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female adults aged \u2265 40 years with a diagnosis of COPD\n\n          -  Current smokers or ex-smokers\n\n          -  A post-bronchodilator FEV1 < 50% of the predicted normal value and a post-\n             bronchodilator FEV1/FVC < 0.7\n\n          -  At least one exacerbation in the 12 months preceding the screening visit\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Diagnosis of asthma or history of allergic rhinitis or atopy\n\n          -  Patients treated with non-cardioselective \u03b2-blockers in the month preceding the\n             screening visit\n\n          -  Patients treated for exacerbations in the 4 weeks prior to screening visit\n\n          -  Patients treated with long-acting antihistamines  unless taken at stable regimen at\n             least 2 months prior to screening and to be maintained constant during the study or\n             if taken as PRN\n\n          -  Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic\n             hypoxemia\n\n          -  Known respiratory disorders other than COPD\n\n          -  Patients who have clinically significant cardiovascular condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "1863", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917331", 
            "org_study_id": "CCD-1207-PR-0091"
        }, 
        "intervention": [
            {
                "arm_group_label": "Beclometasone/Formoterol/Glycopyrrolate", 
                "intervention_name": "Beclometasone/Formoterol/Glycopyrrolate", 
                "intervention_type": "Drug", 
                "other_name": "BDP/FF/GB or CHF 5993 pMDI 100/6/12.5 mcg"
            }, 
            {
                "arm_group_label": "Beclometasone/Formoterol", 
                "intervention_name": "Beclometasone/Formoterol", 
                "intervention_type": "Drug", 
                "other_name": "Foster\u00ae or CHF 1535 pMDI 100/6 mcg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Beclomethasone", 
                "Formoterol", 
                "Glycopyrrolate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "spirometry", 
            "severe COPD", 
            "lung disease", 
            "fixed combination"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "balint@deszkikorhaz.hu", 
                "last_name": "Beatrix BALINT, Dr", 
                "phone": "0036-62-571-512"
            }, 
            "facility": {
                "address": {
                    "city": "Szeged", 
                    "country": "Hungary", 
                    "zip": "6722"
                }, 
                "name": "Dr Beatrix BALINT"
            }, 
            "investigator": {
                "last_name": "Beatrix Balint, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Hungary"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone+Formoterol+Glycopyrrolate to Foster\u00ae in Patients With Chronic Obstructive Pulmonary Disease", 
        "overall_contact": {
            "email": "m.minetti@chiesi.com", 
            "last_name": "Marisa MINETTI", 
            "phone": "+39 0521 279 715"
        }, 
        "overall_contact_backup": {
            "email": "c.francisco@chiesi.com", 
            "last_name": "Catherine FRANCISCO", 
            "phone": "+33 1 47 68 48 59"
        }, 
        "overall_official": {
            "affiliation": "University Hospital of South Manchester, MANCHESTER M23 9 QZ, UK", 
            "last_name": "Dave SINGH, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Czech Republic: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Italy: The Italian Medicines Agency", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Slovakia: State Institute for Drug Control", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Ukraine: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in pre-dose morning FEV1 at Week 26.\nChange from baseline to the 2-hour post-dose value of FEV1 at Week 26.\nTDI focal score at Week 26", 
            "measure": "Pre-dose and 2-hour post-dose morning FEV1 at week 26 and TDI score at week 26", 
            "safety_issue": "No", 
            "time_frame": "week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917331"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Moderate and severe COPD exacerbation rate over 52 weeks of treatment", 
            "measure": "COPD exacerbation rate", 
            "safety_issue": "No", 
            "time_frame": "week 52"
        }, 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}